WO2013003353A3 - Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages - Google Patents
Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages Download PDFInfo
- Publication number
- WO2013003353A3 WO2013003353A3 PCT/US2012/044206 US2012044206W WO2013003353A3 WO 2013003353 A3 WO2013003353 A3 WO 2013003353A3 US 2012044206 W US2012044206 W US 2012044206W WO 2013003353 A3 WO2013003353 A3 WO 2013003353A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vlps
- virus
- particles
- valency
- production
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 241001515965 unidentified phage Species 0.000 title abstract 3
- 238000003314 affinity selection Methods 0.000 title 1
- 239000013612 plasmid Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 2
- 239000000539 dimer Substances 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 101710132601 Capsid protein Proteins 0.000 abstract 1
- 101710094648 Coat protein Proteins 0.000 abstract 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 abstract 1
- 101710125418 Major capsid protein Proteins 0.000 abstract 1
- 101710141454 Nucleoprotein Proteins 0.000 abstract 1
- 101710083689 Probable capsid protein Proteins 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18123—Virus like particles [VLP]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 or PP7 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on bacteriophage VLPs, especially MS2 or PP7 VLPs over a wide range, from few than one- on average- to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of bacteriophage such as MS2 or PP7 modified by insertion of a heterologous peptide, optionally comprising a carbohydrate mimotope, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates bacteriphage mRNA.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/104,844 US20140106982A1 (en) | 2009-12-31 | 2013-12-12 | Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503188P | 2011-06-30 | 2011-06-30 | |
| US61/503,188 | 2011-06-30 |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/520,057 Continuation-In-Part US9365831B2 (en) | 2009-12-31 | 2010-12-31 | Plasmids and methods for peptide display and affinity-selection on virus-like particles of RNA bacteriophages |
| PCT/US2010/062638 Continuation-In-Part WO2011082381A2 (en) | 2009-12-31 | 2010-12-31 | Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/104,844 Continuation US20140106982A1 (en) | 2009-12-31 | 2013-12-12 | Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2013003353A2 WO2013003353A2 (en) | 2013-01-03 |
| WO2013003353A3 true WO2013003353A3 (en) | 2013-09-19 |
Family
ID=47424765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2012/044206 WO2013003353A2 (en) | 2009-12-31 | 2012-06-26 | Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2013003353A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549976B1 (en) | 2012-11-16 | 2017-01-24 | Stc.Unm | Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles |
| WO2015038708A1 (en) | 2013-09-12 | 2015-03-19 | Stc.Unm | Malaria vaccine |
| CN103923887A (en) * | 2014-04-16 | 2014-07-16 | 辽宁医学院 | Pseudoviral particle containing hepatitis e virus RNA (Ribose Nucleic Acid) fragment and preparation method thereof |
| WO2016112921A1 (en) | 2015-01-15 | 2016-07-21 | University Of Copenhagen | Virus-like particle with efficient epitope display |
| ES2854726T3 (en) | 2015-10-30 | 2021-09-22 | The Univ Of Copenhagen | Virus-like particle with efficient epitope presentation |
| US10588953B2 (en) | 2015-12-18 | 2020-03-17 | Agilvax, Inc. | Compositions and methods related to xCT peptides |
| CN105969786B (en) * | 2016-06-07 | 2019-08-02 | 博奥生物集团有限公司 | A kind of plasmid for expressing MS2 phage capsid protein and maturase |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100880477B1 (en) * | 1999-10-14 | 2009-01-28 | 더 다우 케미칼 캄파니 | Viral Particles with Exogenous Internal Epitopes |
| JP2010538619A (en) * | 2007-09-11 | 2010-12-16 | ユニベルシテ ラヴァル | Malva mosaic virus and virus-like particles and their use |
-
2012
- 2012-06-26 WO PCT/US2012/044206 patent/WO2013003353A2/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100880477B1 (en) * | 1999-10-14 | 2009-01-28 | 더 다우 케미칼 캄파니 | Viral Particles with Exogenous Internal Epitopes |
| JP2010538619A (en) * | 2007-09-11 | 2010-12-16 | ユニベルシテ ラヴァル | Malva mosaic virus and virus-like particles and their use |
Non-Patent Citations (4)
| Title |
|---|
| BRYCE CHACKERIAN ET AL.: "Peptide Epitope Identification by Affinity Selection on RNA bacteriophage MS2 Virus-Like Particles.", JOURNAL OF MOLECULAR BIOLOGY, vol. 409, no. ISSUE, 9 April 2011 (2011-04-09), pages 225 - 237 * |
| DAVID S. PEABODY ET AL.: "Immunogenic Display of Diverse Peptides on Virus-like Particles of RNA Phage MS2.", JOURNAL OF MOLECULAR BIOLOGY, vol. 380, no. ISSUE, 2008, pages 252 - 263 * |
| JERRI C. CALDEIRA ET AL.: "Thermal stability of RNA phage virus-like particles displaying foreign peptides.", JOURNAL OF NANOBIOTECHNOLOGY., vol. 9, no. 2, 24 May 2011 (2011-05-24), pages 1 - 7 * |
| VANCE P. LOCHRIDGE ET AL.: "Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions.", JOURNAL OF GENERAL VIROLOGY, vol. 86, 2005, pages 2799 - 2806 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013003353A2 (en) | 2013-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011082381A3 (en) | Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages | |
| WO2013003353A3 (en) | Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages | |
| MY182643A (en) | Chimeric influenza virus-like particles comprising hemagglutinin | |
| WO2013082317A3 (en) | Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof | |
| WO2013063383A3 (en) | Vectors encoding rod-derived cone viability factor | |
| WO2012083445A8 (en) | Virus like particle production in plants | |
| WO2012061815A3 (en) | RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs) | |
| IL236650B (en) | Immunogenic combination, nucleic acids or vectors encoding it, host cells or compositions comprising them, and therapeutic uses thereof, process of producing an infectious virus and method for recombinant production of the mycobacterial antigens | |
| WO2015191693A3 (en) | Method for gene editing | |
| WO2013164793A3 (en) | Viral vectors for the treatment of retinal dystrophy | |
| MX342608B (en) | Virion-like delivery particles for self-replicating rna molecules. | |
| WO2017218974A3 (en) | Treatment of amd using aav2 variant with aflibercept | |
| WO2013052167A3 (en) | Membrane encapsulated nanoparticles and method of use | |
| WO2010118424A3 (en) | Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines | |
| WO2017040387A3 (en) | Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine | |
| MX2014000753A (en) | Process for producing viral antigen and vaccines. | |
| MX2018004016A (en) | Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof. | |
| EP3882351A4 (en) | Recombinant vector for expressing virus-like particles in plant and method for preparation of vaccine composition containing circovirus-like particles by using same | |
| MX2019005298A (en) | Compositions and methods using capsids resistant to hydrolases. | |
| PH12020550169A1 (en) | Isothiocyanate containing brassicaceae products and method of preparation thereof | |
| WO2011090712A3 (en) | Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions | |
| NZ622731A (en) | Increasing virus-like particle yield in plants | |
| MX2019015925A (en) | Virus-like particles comprising zika antigen. | |
| WO2014116730A3 (en) | Stabilized hepatitis b core polypeptide | |
| WO2015038915A3 (en) | Compositions and methods using capsids resistant to hydrolases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12805362 Country of ref document: EP Kind code of ref document: A2 |